Detailed explanation of the efficacy and functions of venetoclax/venetoclax tablets

Venetoclax/Venetoclax is a targeted drug targeting B-cell lymphoma 2 (BCL-2) family proteins. It is mainly used to treat chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). Proteins in the BCL-2 family play important roles in regulating the apoptosis process and include pro-apoptotic and pro-survival proteins. Cancer cells survive and proliferate by evading normal cell death through mechanisms that inhibit programmed cell death (i.e., apoptosis).

Venetoclax selectively inhibitsBCL-2 protein while retaining BCL-xL, which has the therapeutic potential to induce apoptosis. Unlike the earlier developed navitoclax, venetoclax's specificity for BCL-2 enables it to effectively induce apoptosis in cancer cells without causing significant thrombocytopenia side effects. The drug helps restore the normal apoptotic process by directly binding to the BCL-2 protein, displacing pro-apoptotic proteins, leading to permeabilization of the outer mitochondrial membrane and activation of caspases.

In non-clinical studies, venetoclax has been shown to exhibit significant cytotoxic activity in tumor cells overexpressingBCL-2. Studies have shown that it can rapidly induce apoptosis in CLL cells, with effects usually observed within 24 hours. This rapid response may lead to the occurrence of tumor lysis syndrome. In addition, venetoclax has a favorable safety profile and has shown significant treatment responses in patients with relapsed CLL or SLL, including those with poor prognosis.

Venetoclax is effective against multiple types of lymphoid malignancies, including relapsed or refractory CLL containing deletion17p, with an overall efficacy rate of up to 80%. This makes venetoclax an important option for the treatment of these complex cases. It is important to note that the effect of venetoclax on the cardiac QT interval is not expected to be significant, making its use relatively safe. This property further enhances the application prospects of venetoclax as an emerging anti-tumor drug.

Reference materials:https://go.drugbank.com/drugs/DB11581